Study of combined methotrexate and phototherapy in vitiligo.
Phase 3
- Conditions
- Vitiligo.
- Registration Number
- IRCT20221013056158N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
Known case of vitiligo
No systemic or local immunosuppressive treatment in past 6 months
Vitiligo disease activity more than one
Candidates for phototherapy
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of vitiligo disease. Timepoint: Before treatment, after 2 months, 4 months and 6 months of treatment. Method of measurement: Vitiligo Area Scoring Index.;Vitiligo activity. Timepoint: Before treatment then after 2 months, 4 months and 6 months of treatment. Method of measurement: Vitiligo Disease Activity Scorings.
- Secondary Outcome Measures
Name Time Method